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Introduction
Erectile dysfunction (ED) is considered one of the
most commonly occurring male sexual disorders
(1–3). The high prevalence of ED, as reported in
publications on male sexual dysfunction, imposes a
signiﬁcant burden on male health and interpersonal
relationships (2,4–9). Approximately 70% of men
with ED experience at least one of the following
comorbid conditions: hypertension, hyperlipidaemia,
diabetes mellitus or depression (7). Because of shared
pathophysiological mechanisms, ED is regarded as a
sentinel marker of underlying vascular abnormalities
(1,10–12). Furthermore, men with ED often do not
seek proper medical attention for fear of embarrass-
ment and⁄or ridicule (13).
In clinical trials, the efﬁcacy of pharmacological
agents, including the phosphodiesterase type 5
(PDE5) inhibitors, in the treatment of ED has tradi-
tionally been measured by means of patient diaries
and questionnaires. These include the Erectile Func-
tion domain of the International Index of Erectile
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measuring the duration of erection leading to successful intercourse using a stop-
watch as the assessment instrument. Methods: This was a randomised, multicen-
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5.45 ± 1.00 min; p < 0.001). The differences recorded for all secondary end-
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(p < 0.001), with the exception of duration of erection not leading to successful
intercourse. Vardenaﬁl was well tolerated in this study; the majority of AEs being
mild-to-moderate in intensity. Conclusion: Vardenaﬁl 10-mg therapy provided a
statistically superior duration of erection leading to successful intercourse in men
with ED compared with placebo.
What’s known
The efﬁcacy of phosphodiesterase type 5 (PDE5)
inhibitors in restoring erectile function in men with
erectile dysfunction (ED) has been evaluated
primarily by means of patient-reported outcome
measures, including questionnaires and performance
scoring.
What’s new
This is the ﬁrst clinical study in which a stopwatch
approach was used to measure accurately the
duration of erection as it pertains to successful
intercourse during PDE5 inhibitor therapy. Results
demonstrate that treatment with vardenaﬁl is
associated with an increased duration of erection
and restoration of erectile function compared with
placebo.
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Questions, which include SEP 2 (‘Were you able to
insert your penis into your partner’s vagina?’) and
SEP 3 (‘Did your erection last long enough for you
to have successful intercourse?’) and a global assess-
ment question (GAQ; ‘Has the treatment you have
been taking over the past 4 weeks improved your
erections? Yes⁄No’). The objective of these studies
was to assess the effects of vardenaﬁl and placebo on
penetration and maintenance of erection leading to
successful sexual intercourse (14–16). Regulatory
approval of the PDE5 inhibitors currently available
in the USA – vardenaﬁl (17), sildenaﬁl (18) and tad-
alaﬁl (19) – was based primarily on results obtained
with these assessment tools.
Data show that men receiving PDE5 inhibitor
therapy have improvement in penile hardness and
maintenance of erection, which help them achieve
successful intercourse (20,21). However, a stopwatch
measurement of the actual duration of erection has
not been utilised in a majority of clinical evaluations
as an efﬁcacy variable.
ENDURANCE is the ﬁrst study in which a stop-
watch assessment tool was used to measure duration
of erection leading to successful intercourse as a pri-
mary efﬁcacy end-point following PDE5 inhibitor
therapy. The aim was to demonstrate, through the
use of this method of assessment, that the PDE5
inhibitor vardenaﬁl improved the duration of erec-
tion in men with ED, when compared with a placebo
treatment. Stopwatch-assessed duration of erection
obtained in this study has also been correlated with
the more traditional patient-reported outcome mea-
surements in a separate analysis and found to be well
correlated to SEP3 and the EF domain of the
IIEF (22).
Methods
Study objective
The primary objective of the ENDURANCE study
was to determine whether ﬁxed-dose vardenaﬁl
10 mg taken on-demand increased the duration of
erection leading to successful intercourse (SEP-3)
when compared with placebo in patients with ED.
Study design
ENDURANCE was a randomised, multicentre,
double-blind, placebo-controlled crossover study
designed to compare the duration of erection in men
with ED receiving ﬁxed-dose vardenaﬁl 10 mg or
placebo over a 4-week treatment period. The study
consisted of a screening phase, a run-in phase, two
treatment phases and a washout period. The proto-
col, informed consent and other required documents
were reviewed and approved by a national, regional
or investigational centre independent ethics commit-
tee or institutional review board.
Following initial screening, patients entered a
4-week treatment-free, run-in period, during which
they were instructed to make at least four attempts
at intercourse on four separate days. At least 50% of
attempts had to be unsuccessful (see inclusion⁄exclu-
sion criteria) to qualify for the continuation into the
study. Eligible patients from the run-in period were
randomised to receive either ﬁxed-dose vardenaﬁl
10 mg or placebo for 4 weeks. This was followed by
a 1-week wash-out period, more than sufﬁcient to
incur no pharmacokinetic carry over of effect.
Patients were then crossed over to receive the alter-
nate study medication from that received during the
ﬁrst 4-week treatment period (i.e. patients who
started on vardenaﬁl received placebo and those who
started on placebo received vardenaﬁl). Patients were
instructed to take the study medication 60 min prior
to attempting intercourse. Study visits were sched-
uled 4 weeks prior to randomisation; on the day of
randomisation; and 4, 5 and 9 weeks following ran-
domisation.
Inclusion and exclusion criteria
The study enrolled men aged 18–64 years who had
been in a stable heterosexual relationship for more
than 6 months, and who had experienced ED for
more than 6 months, according to the National
Institutes of Health Consensus Statement (6). In
addition, patients had to make at least four attempts
at sexual intercourse according to the question in the
patient diary (‘Was sexual activity initiated with the
intention of intercourse?’) on four separate days,
during the untreated run-in period. At least 50% of
attempts had to be unsuccessful as determined
by the following questions from the patient diary:
‘Were you able to achieve at least some erection
(some enlargement of the penis)?’ (SEP-1); ‘Were
you able to insert your penis into your partner’s
vagina?’ (SEP-2) and ‘Did your erection last long
enough for you to have successful intercourse?’
(SEP-3). An unsuccessful attempt was deﬁned by a
‘No’ answer to at least one of these questions.
Finally, patients had to register an IIEF-EF domain
score of > 5 and < 26 on the second scheduled
(randomisation) visit.
The exclusion criteria comprised premature ejacu-
lation (deﬁned as intravaginal ejaculatory latency
time < 2 min), penile anatomical abnormalities, pri-
mary hypoactive sexual desire, spinal cord injury,
retinitis pigmentosa or surgical prostatectomy.
Patients with the following conditions were also
excluded from the study: severe chronic liver disease;
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tions; bleeding disorders; signiﬁcant active peptic
ulceration; underlying cardiovascular conditions,
including unstable angina pectoris; history of
myocardial infarction, stroke, or life-threatening
arrhythmia within 6 months of study entry; or rest-
ing⁄symptomatic hypotension. Patients previously
unresponsive to PDE5 inhibitor treatments were
excluded as well. The following concomitant medica-
tions were not allowed: nitrates or nitric oxide
donors, anti-androgens, oral or injectable androgens,
anticoagulants (except for antiplatelet agents) and
alpha blockers. Patients who received any investiga-
tional drug (including placebo) within 30 days of
screening were ineligible. All patients had to com-
plete written informed consent prior to the study.
Efﬁcacy assessment
The primary efﬁcacy end-point of this study was the
duration of erection leading to successful intercourse
as measured by SEP-3. Duration of erection, timed
with a stopwatch, was deﬁned as the time from erec-
tion perceived hard enough for penetration (start
stopwatch) until withdrawal from the partner’s
vagina (stop stopwatch). Secondary efﬁcacy end-
points included success of insertion as measured by
response to SEP-2, success of maintenance of erec-
tion as measured by response to SEP-3, erectile func-
tion measured by the IIEF-EF domain score and
response to the GAQ. Additional secondary efﬁcacy
end-points related to the time component of the
measuring instrument including duration of erection
regardless of SEP-3 response, duration of erection
that did not lead to successful intercourse as mea-
sured by SEP-3 and the change from baseline in
duration of erection. The secondary end-points were
not adjusted for multiplicity.
Safety assessment
Safety and tolerability were evaluated throughout the
course of the study by assessing adverse events (AE),
clinical chemistry, haematology and urinalysis, 12-
lead ECG and vital signs.
Statistical methods
The intent-to-treat (ITT) population, the population
to be used for the efﬁcacy analyses, consisted of
patients who were administered at least one dose of
study medication and for whom postrandomisation
safety data and baseline and postbaseline efﬁcacy data
were collected. The safety population, the population
for safety summaries, were administered at least one
dose of study medication and had postrandomisation
safety data collected. According to prestudy sample
size calculations, 150 patients were needed to detect a
moderate effect size (i.e. ratio of the mean to its SD)
of 0.375 with a two-sided signiﬁcance level of 0.05
and power of at least 90%. Assuming a 20% screen
failure rate and a 25% dropout rate, 250 patients had
to be screened to randomise 200. The primary efﬁ-
cacy hypothesis was tested at the two-sided 5% signif-
icance level to determine if the duration of erection
leading to successful intercourse (SEP-3) with varde-
naﬁl was superior to that with placebo after 4 weeks
of treatment with both therapies. Similar hypotheses
were also tested for secondary end-points with no
adjustment for multiplicity. The median of the mea-
surements of the primary efﬁcacy variable [duration
of erection leading to successful intercourse (SEP-3)]
was calculated for each patient then averaged sepa-
rately for each treatment. Similar medians were also
calculated for the secondary efﬁcacy end-points
involving duration of erection. The responses for each
treatment were compared by a mixed effects model
ﬁtting terms for sequence, period, patient within
sequence and treatment. The patient was ﬁtted as a
random effect. A point estimate and corresponding
95% conﬁdence interval were constructed for the dif-
ference between treatments in duration of erection
leading to successful intercourse. Similar mixed
effects models were also used for the continuous sec-
ondary efﬁcacy end-points. The binary end-point
GAQ was analysed using a Mainland-Gart test. To be
included in an analysis, a patient must have received
both treatments.
Results
Patient demographics
Of the 346 patients screened for the study, 201 were
randomised into the treatment phase, 175 completed
the study and 191 were included in the safety and
ITT populations. The baseline demographics and ED
characteristics of patients in the safety population are
displayed in Tables 1 and 2. Patients enrolled in the
study had a mean age of approximately 49 years,
with a 3.9 years mean duration of ED. Ten per cent
of patients used alcohol in moderation, 55% lightly
and there was a high incidence of past or present
tobacco use (44%, greater than twice the national
average) (23) (Table 1). Of the 191 randomised
patients included in the safety population, 40% had
moderate ED and 33% had severe ED, with a mean
baseline IIEF-EF domain score of 13.3 ± 4.6
(Table 2). Baseline comorbidities included hyperten-
sion (32%), hypercholesterolaemia (14%), hyperlip-
idaemia (10%) and diabetes mellitus (7%) (Table 3).
The reasons most frequently cited for premature
discontinuation from the study (n = 26) were with-
drawal of consent (n = 10), lost to follow-up (n =9 )
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because of an AE and one patient withdrew because
of lack of therapeutic effect of the study medication.
Almost three-quarters of patients in the safety popu-
lation had previously used a PDE5 inhibitor, with sil-
denaﬁl used most frequently (69%) (Table 3).
Efﬁcacy
A total of 191 men were included in the ITT popula-
tion. During the 4-week treatment period, the least
squares (LS) mean duration of erection leading to
successful intercourse was statistically superior when
patients were treated with vardenaﬁl compared with
when patients were treated with placebo (12.81
± 1.00 min vs. 5.45 ± 1.00 min; p < 0.001; n = 159;
LS mean ± SE) (Figure 1). This resulted in a differ-
ence of 7.36 min between the two treatments (95%
conﬁdence interval: 5.04–9.67).
Secondary efﬁcacy end-points also demonstrated
statistically signiﬁcant superiority with vardenaﬁl
compared with placebo in the same patients,
although data were not adjusted for multiple com-
parisons. Over the 4-week treatment period, the LS
mean success rate for SEP-2 was signiﬁcantly higher
when patients received vardenaﬁl compared with
when patients received placebo (85.51% vs. 57.78%;
p < 0.001; n = 159). The difference between the two
treatments in LS mean success rate for SEP-2 was
27.73% (95% conﬁdence interval: 21.18–34.28)
(Figure 2A). The LS mean success rate for SEP-3 was
signiﬁcantly higher when patients were treated
with vardenaﬁl compared with patients treated with
Table 1 Baseline demographic data (safety population)
Demographic All patients, N = 191
Age (years)
Mean (SD) 49.0 (9.9)
Minimum–maximum 21–64
Race, n (%)
White 131 (69)
Hispanic 29 (15)
Black 25 (13)
Asian 5 (3)
Other 1 (< 1)
Height (cm)
Mean (SD) 176.6 (8.0)
Minimum–maximum 152–203
Weight (kg)
Mean (SD) 92.6 (20.5)
Minimum–maximum 57–189
BMI (kg⁄m
2)
Mean (SD) 29.6 (6.0)
Minimum–maximum 19–58
Alcohol use, n (%)
Abstinent 62 (32)
Light 106 (55)
Moderate 20 (10)
Heavy 3 (2)
Smoking status, n (%)
Non-smoker 106 (55)
Smoker, past or present 84 (44)
Passive smoker 1 (< 1)
Marital status, n (%)
Married 135 (71)
Never married 35 (18)
Divorced 20 (10)
Widowed 1 (< 1)
BMI, body mass index.
Table 2 Baseline ED characteristics (safety population)
Baseline disease characteristic All patients, N = 191
ED aetiology, n (%)
Organic 92 (48)
Mixed 93 (49)
Psychogenic 6 (3)
Years since ED ﬁrst noticed
Mean (SD) 4.9 (4.6)
Minimum–maximum 1–30
Years since ED diagnosis
Mean (SD) 3.9 (4.0)
Minimum–maximum 0–23
ED severity, n (%)
Total ED (£ 5) 0
Severe (6–10) 63 (33)
Moderate (11–16) 77 (40)
Mild⁄moderate (17–21) 43 (23)
Mild (22–25) 8 (4)
EF domain score
Mean (SD) 13.3 (4.6)
Minimum–maximum 6–25
EF, erectile function; ED, erectile dysfunction.
Table 3 Summary of select comorbidities and previous
PDE5 use at baseline (safety population, N = 191)
Comorbidities, n (%)
Hypertension 61 (32)
Hypercholesterolaemia 26 (14)
Depression 26 (14)
Hyperlipidaemia 20 (10)
Diabetes 13 (7)
Prior PDE5 inhibitor use, n (%)
Sildenaﬁl 131 (69)
Tadalaﬁl 37 (19)
Vardenaﬁl 46 (24)
PDE5, phosphodiesterase type 5.
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(Figure 2B). The difference in LS mean values was
37.05% (95% conﬁdence interval: 29.03–45.06).
Patients also reported statistically signiﬁcant impro-
vements in erectile function while receiving vardena-
ﬁl compared with when receiving placebo in terms
of the IIEF-EF domain score (23.42 vs. 16.31;
p < 0.001; n = 175). The difference in LS mean was
7.11 (95% conﬁdence interval: 5.66–8.56) (Figure 2C).
In addition, a greater response was reported follow-
ing vardenaﬁl treatment vs. placebo, as evidenced by
the percent of patients with a ‘yes’ response to the
GAQ, which asked ‘Has the treatment you have
been taking over the past 4 weeks improved your
erections?’ (74% vs. 26%; p < 0.001; n = 175)
(Figure 2D). The duration of erection regardless of
SEP-3 response was also signiﬁcantly greater when
patients were receiving vardenaﬁl compared with
when they received placebo (13.60 ± 0.99 min vs.
7.59 min ± 0.99; p < 0.001; n = 159). The difference
in LS mean was 6.01 min (95% conﬁdence interval:
3.8–8.22). When the duration of erection was
assessed in attempts where patients did not achieve
successful intercourse as measured by response to
SEP-3, a statistically non-signiﬁcant increase was
observed when patients received placebo compared
with their vardenaﬁl treatment (4.31 ± 0.86 min vs.
3.39 min ± 0.86; p = 0.377; n = 59). The difference
in LS mean was )0.92 (conﬁdence interval 95%: )3
to 1.15). The change from baseline in duration of
erection leading to successful intercourse (for the 159
patients receiving both treatments) was 12.18 ±
0.98 min when treated with vardenaﬁl and 4.82 ±
0.98 min when treated with placebo (LS mean ± SE),
a difference of 7.36 min (95% conﬁdence interval:
5.04–9.67; p < 0.001) (Figure 2E).
Safety
Vardenaﬁl was well tolerated, with the majority of
AEs being mild-to-moderate in intensity. The most
frequently reported treatment-emergent (began after
start of study medication up to 24 h after last dose
study medication) AEs (‡ 3%) in patients receiving
vardenaﬁl therapy were headache (3%) and ﬂushing
(5%). AEs occurring with an incidence of at least
1% are shown in Table 4. One patient reported a
serious occurrence of cholecystitis while receiving
vardenaﬁl that investigators did not consider drug-
related, and another patient reported an occurrence
of moderate syncope while receiving vardenaﬁl that
resulted in his discontinuation of treatment. This
event was considered drug-related, according to the
investigator. Vardenaﬁl had no clinically relevant
effects on laboratory parameters, vital signs or
ECGs.
Discussion
Traditional methods for measuring the efﬁcacy of
PDE5 inhibitors relied on patients’ responses to self-
administered questionnaires, including the IIEF-EF
domain score, SEP-2, SEP-3 and GAQ, diaries or
event logs and interviews (24–26). The main objec-
tive of these questionnaires has been to evaluate the
effect of PDE5 inhibitors on penetration and mainte-
nance of erection.
Although stopwatch measurements have been pre-
viously used to quantify the onset of action of PDE5
inhibitors (27–29), ENDURANCE was the ﬁrst study
in which duration of erection with PDE5 therapy
was quantitatively measured as a primary efﬁcacy
end-point. A stopwatch approach was used to record
accurately in minutes the duration of erection
leading to successful intercourse in men with ED.
This method thus provided an objective and quanti-
tative measure of the effects of ﬁxed-dose vardenaﬁl
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Figure 1 Duration of erection (in minutes) leading to
successful intercourse. LS mean duration of erection for
vardenaﬁl (12.81 min) and for placebo (5.45 min) over the
4-week treatment period in patients receiving both
treatments (n = 159), a difference of 7.36 min (95% CI:
5.04–9.67) in favour of vardenaﬁl (p < 0.001)
Table 4 Most frequently reported adverse events by
patients (‡ 1%) while receiving assigned treatment
(safety population, N = 191)
Adverse event
Placebo,
N = 184, n (%)
Vardenaﬁl,
N = 187, n (%)
Any event 20 (11) 32 (17)
Flushing 5 (3) 10 (5)
Headache 4 (2) 5 (3)
Nasal congestion 0 3 (2)
Acute bronchitis 0 2 (1)
Cough 0 2 (1)
Upper respiratory
tract infection
3 (2) 1 (< 1)
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Figure 2 Improvement in erectile function as assessed by SEP-2, SEP-3, IIEF-EF domain score and GAQ in the ITT population, and by change from
baseline in duration of erection leading to successful intercourse. Least-square mean scores for individual questions in the patient diary and on the
IIEF-EF domain at baseline and after 4 weeks of treatment with either vardenaﬁl 10 mg or placebo. Only men receiving both treatments were
included (SEP-2, SEP-3, change from baseline in duration of erection leading to successful intercourse; n = 159, IIEF-EF domain and GAQ;
n = 175). (A) SEP-2 (Were you able to insert your penis into your partner’s vagina?); (B) SEP-3 (Did your erection last long enough for you to have
successful intercourse?); (C) IIEF-EF domain scores; (D) Percentage of the ITT population responding ‘yes’ to the GAQ ‘Has the treatment you have
been taking over the past 4 weeks improved your erections? (Yes⁄No)’. The difference between treatments was statistically signiﬁcant in all cases
(p < 0.001). (E) Change from baseline in duration of erection leading to successful intercourse in patients receiving both treatments
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as-needed basis 60 min prior to intercourse. Primary
efﬁcacy results indicated that patients experienced a
greater than two-fold improvement in duration of
erection leading to successful intercourse (SEP-3)
during a 4-week period when taking vardenaﬁl
compared with placebo. Scores for the validated
IIEF-EF domain erectile function scale, as well as
success rates for SEP-2 and SEP-3, paralleled those
obtained with stopwatch measurements. Overall,
vardenaﬁl was well tolerated, and the rate and type
of AEs reported were consistent with the safety pro-
ﬁle of PDE5 inhibitors.
While traditional methods for measuring duration
of erection provided some qualitative measures of
erectile function in men with ED, the addition of a
quantitative measure, such as the stopwatch-assessed
duration of erection and its comparison with the
currently accepted patient-reported outcome mea-
surements (SEP and IIEF) (22), suggests that it may
be a reliable measure of erectile function and could
be suitable for use as a primary end-point in future
efﬁcacy trials. In vitro, vardenaﬁl is a potent and
selective PDE5 inhibitor (30). Although in vitro afﬁn-
ity does not necessarily translate into potency in vivo,
the robust effect observed in the ENDURANCE
study may in part be attributed to the strong afﬁnity
of vardenaﬁl for the PDE5 receptor. This warrants
further investigation.
Conclusion
The efﬁcacy of vardenaﬁl over placebo has been
documented many times, but never using a stop-
watch to quantify the response in a reproducible
objective fashion. In the ﬁrst PDE5 inhibitor study
that assessed duration of erection as a primary efﬁ-
cacy end-point, vardenaﬁl 10 mg produced a statis-
tically superior duration of erection leading to
successful intercourse vs. placebo in a general popu-
lation of men with ED. The results of this study
represent an alternative, more objective approach
than self-assessment to quantify accurately the efﬁ-
cacy of PDE5 inhibitors in future clinical trials. The
stopwatch approach has the opportunity to become
the method of choice for efﬁcacy comparisons in
the future.
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